Combining from-home sample collection with genomic monitoring, DxTerity’s® proprietary technologies are transforming the management of immune-mediated disease while enhancing recruitment and clinical study efficiencies.
More than 400,000 Americans are living with Multiple Sclerosis (MS), a chronic condition that affects the central nervous system. MS onset, progression and response to treatment is very individualized and can range widely from person to person. There are numerous MS drugs available, but their degree of benefit to each person may vary. The ability to predict how or if a particular person will respond to a given therapy could help doctors and individuals with MS better manage, and even get ahead of, their disease. In the EMPOWER study (Evaluating Multiple Sclerosis Patients ShOWing A GEnomic Signature of Therapy Response) researchers are developing an at-home blood test that will help doctors monitor Multiple Sclerosis (MS) disease activity and response to treatment at a biological level.
Lupus is a chronic, autoimmune disease that occurs when — for unknown reasons — the immune system turns on itself, attacking healthy tissue and organs. For the 1.5 million Americans living with lupus, there are no affordable or easy tools to manage it on a regular basis. While more treatments have become available, many patients still experience uncontrolled disease activity and painful flares. In LIFT (Lupus Interval Monitoring to Manage Disease Flare and Enable Treatment Optimization), researchers are developing an at-home blood test to help physicians monitor lupus disease activity and measure response to therapy.
More than 2.4 million Americans have rheumatoid arthritis, a chronic autoimmune disease that occurs when a person’s immune system becomes compromised causing inflammation and deterioration in the joints. Currently, there are no affordable or convenient tools to manage rheumatoid arthritis on a regular basis. In BRAVO (Baseline Rheumatoid Arthritis Verification Outcomes), researchers are developing an at-home blood test to help physicians monitor rheumatoid arthritis disease activity and measure response to therapy.
Radiation therapy or radiotherapy is one of the most widely prescribed treatments for cancer in the US, with approximately 60% of all cancer patients, or more than one million people receiving some form of radiation therapy in 2015 alone. But despite its excellent safety profile, approximately 10% of patients will experience an adverse reaction to the therapy, while many patients experience no curative benefit. In RADIANT (Radiotherapy Assessments During Intervention ANd Treatment), researchers are developing a blood test that will help doctors assess a patient’s likelihood of responding to radiation and contribute to identifying those who are likely to experience an adverse response to the treatment. This capability will enable doctors to make more informed treatment decisions and guide them in providing a more appropriate treatment for their cancer patients.